{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:05:35Z","timestamp":1789506335761,"version":"build-2803163510"},"reference-count":52,"publisher":"Bentham Science Publishers Ltd.","issue":"10","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872798"],"award-info":[{"award-number":["81872798"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U1909208"],"award-info":[{"award-number":["U1909208"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21505009"],"award-info":[{"award-number":["21505009"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LR21H300001"],"award-info":[{"award-number":["LR21H300001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"publisher","award":["2018YFC0910500"],"award-info":[{"award-number":["2018YFC0910500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Fund for Central Universities","doi-asserted-by":"publisher","award":["2018QNA7023"],"award-info":[{"award-number":["2018QNA7023"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Fund for Central Universities","doi-asserted-by":"publisher","award":["2019CDYGYB005"],"award-info":[{"award-number":["2019CDYGYB005"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Fund for Central Universities","doi-asserted-by":"publisher","award":["CDJKXB-14011"],"award-info":[{"award-number":["CDJKXB-14011"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013145","name":"Key R&D Program of Zhejiang Province","doi-asserted-by":"publisher","award":["2020C03010"],"award-info":[{"award-number":["2020C03010"]}],"id":[{"id":"10.13039\/501100013145","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Acquired immunodeficiency syndrome (AIDS) has been a chronic, life-threatening\ndisease for a long time. Though, a broad range of antiretroviral drug regimens is applicable\nfor the successful suppression of virus replication in human immunodeficiency virus type 1\n(HIV-1) infected people. The mutation-induced drug resistance problems during the treatment\nof AIDS forced people to continuously look for new antiviral agents. HIV-1 integrase (IN)\nand reverse transcriptase associated ribonuclease (RT-RNase H), two pivotal enzymes in\nHIV-1 replication progress, have gained popularity as druggable targets for designing novel\nHIV-1 antiviral drugs. During the development of HIV-1 IN and\/or RT-RNase H inhibitors,\ncomputer-aided drug design (CADD), including homology modeling, pharmacophore, docking,\nmolecular dynamics (MD) simulation and binding free energy calculation, represent a\nsignificant tool to accelerate the discovery of new drug candidates and reduce costs in antiviral\ndrug development. In this review, we summarized the recent advances in the design of single-\nand dual-target inhibitors against HIV-1 IN or\/and RT-RNase H as well as the prediction\nof mutation-induced drug resistance based on computational methods. We highlighted the results\nof the reported literatures and proposed some perspectives on the design of novel and\nmore effective antiviral drugs in the future.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867328666210708090123","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T03:53:06Z","timestamp":1625802786000},"page":"1664-1676","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Recent Advances in Computer-aided Antiviral Drug Design Targeting HIV-1 Integrase and Reverse Transcriptase Associated Ribonuclease H"],"prefix":"10.2174","volume":"29","author":[{"given":"Weiwei","family":"Xue","sequence":"first","affiliation":[{"name":"School of Pharmaceutical Sciences, Chongqing Key Laboratory of Natural Product Synthesis and Drug Research,\nChongqing University, Chongqing 401331, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhu","sequence":"first","affiliation":[{"name":"School of Pharmaceutical Sciences, Chongqing Key Laboratory of Natural Product Synthesis and Drug Research,\nChongqing University, Chongqing 401331, China"},{"name":"College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengyuan","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Chongqing Key Laboratory of Natural Product Synthesis and Drug Research,\nChongqing University, Chongqing 401331, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Chongqing Key Laboratory of Natural Product Synthesis and Drug Research,\nChongqing University, Chongqing 401331, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Chongqing Key Laboratory of Natural Product Synthesis and Drug Research,\nChongqing University, Chongqing 401331, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gao","family":"Tu","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Chongqing Key Laboratory of Natural Product Synthesis and Drug Research,\nChongqing University, Chongqing 401331, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Yao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Applied Organic Chemistry and\nDepartment of Chemistry, Lanzhou University, Lanzhou 730000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","unstructured":"https:\/\/www.who.int\/health-topics\/hiv-aids"},{"key":"ref=2","doi-asserted-by":"publisher","DOI":"10.4155\/fsoa-2018-0060","volume":"4","author":"Choi E.","year":"2018","unstructured":"Choi E.; Mallareddy J.R.; Lu D.; Kolluru S.; Recent advances in the discovery of small-molecule inhibitors of HIV-1 integrase. Future Sci OA 2018,4(9)","journal-title":"Future Sci OA"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1126\/science.2171144","volume":"249","author":"Bushman F.D.F.","year":"1990","unstructured":"Bushman F.D.F.; Fujiwara T.; Craigie R.; Retroviral DNA integration directed by HIV integration protein in vitro. Science 1990,249(4976),1555-1558","journal-title":"Science"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0065-3527(08)60306-1","volume":"52","author":"Asante-Appiah E.","year":"1999","unstructured":"Asante-Appiah E.; Skalka A.M.; HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv Virus Res 1999,52,351-369","journal-title":"Adv Virus Res"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/QCO.0000000000000327","volume":"30","author":"Elliot E.","year":"2017","unstructured":"Elliot E.; Chirwa M.; Boffito M.; How recent findings on the pharmacokinetics and pharmacodynamics of integrase inhibitors can inform clinical use. Curr Opin Infect Dis 2017,30(1),58-73","journal-title":"Curr Opin Infect Dis"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"4718","DOI":"10.1038\/s41598-019-41403-x","volume":"9","author":"Siwe-Noundou X.","year":"2019","unstructured":"Siwe-Noundou X.; Musyoka T.M.; Moses V.; Ndinteh D.T.; Mnkandhla D.; Hoppe H.; Tastan Bishop \u00d6.; Krause R.W.M.; Anti-HIV-1 integrase potency of methylgallate from alchornea cordifolia using in vitro and in silico approaches. Sci Rep 2019,9(1),4718","journal-title":"Sci Rep"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12977-017-0360-7","volume":"14","author":"Anstett K.","year":"2017","unstructured":"Anstett K.; Brenner B.; Mesplede T.; Wainberg M.A.; HIV drug resistance against strand transfer integrase inhibitors. Retrovirology 2017,14(1),36","journal-title":"Retrovirology"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12977-018-0420-7","volume":"15","author":"Smith S.J.Z.","year":"2018","unstructured":"Smith S.J.Z.; Zhao X.Z.; Burke T.R.; Hughes S.H.; Efficacies of cabotegravir and bictegravir against drug-resistant HIV-1 integrase mutants. Retrovirology 2018,15(1),37","journal-title":"Retrovirology"},{"key":"ref=9","unstructured":"https:\/\/hivdb.stanford.edu\/dr-summary\/resistance-notes\/INSTI\/"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"7086","DOI":"10.1128\/AAC.01474-16","volume":"60","author":"Tsiang M.","year":"2016","unstructured":"Tsiang M.; Jones G.S.; Goldsmith J.; Mulato A.; Hansen D.; Kan E.; Tsai L.; Bam R.A.; Stepan G.; Stray K.M.; Niedziela-Majka A.; Yant S.R.; Yu H.; Kukolj G.; Cihlar T.; Lazerwith S.E.; White K.L.; Jin H.; Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 Integrase Strand Transfer Inhibitor with an improved resistance profile. Antimicrob Agents Chemother 2016,60(12),7086-7097","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.3390\/v7072790","volume":"7","author":"Mespl\u00e8de T.","year":"2015","unstructured":"Mespl\u00e8de T.; Wainberg M.A.; Resistance against integrase strand transfer inhibitors and relevance to hiv persistence. Viruses 2015,7(7),3703-3718","journal-title":"Viruses"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s40265-020-01379-9","volume":"80","author":"Scarsi K.K.H.","year":"2020","unstructured":"Scarsi K.K.H.; Havens J.P.; Podany A.T.; Avedissian S.N.; Fletcher C.V.; HIV-1 integrase inhibitors: A comparative review of efficacy and safety. Drugs 2020,80(16),1649-1676","journal-title":"Drugs"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1093\/jac\/dkw071","volume":"71","author":"Brenner B.G.T.","year":"2016","unstructured":"Brenner B.G.T.; Thomas R.; Blanco J.L.; Ibanescu R.I.; Oliveira M.; Mespl\u00e8de T.; Golubkov O.; Roger M.; Garcia F.; Martinez E.; Wainberg M.A.; Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors. J Antimicrob Chemother 2016,71(7),1948-1953","journal-title":"J Antimicrob Chemother"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","volume":"382","author":"Cahn P.","year":"2013","unstructured":"Cahn P.; Pozniak A.L.; Mingrone H.; Shuldyakov A.; Brites C.; Andrade-Villanueva J.F.; Richmond G.; Buendia C.B.; Fourie J.; Ramgopal M.; Hagins D.; Felizarta F.; Madruga J.; Reuter T.; Newman T.; Small C.B.; Lombaard J.; Grinsztejn B.; Dorey D.; Underwood M.; Griffith S.; Min S.; Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: Week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 2013,382(9893),700-708","journal-title":"Lancet"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1097\/QAD.0000000000001494","volume":"31","author":"Lepik K.J.H.","year":"2017","unstructured":"Lepik K.J.H.; Harrigan P.R.; Yip B.; Wang L.; Robbins M.A.; Zhang W.W.; Toy J.; Akagi L.; Lima V.D.; Guillemi S.; Montaner J.S.G.; Barrios R.; Emergent drug resistance with integrase strand transfer inhibitor-based regimens. AIDS 2017,31(10),1425-1434","journal-title":"AIDS"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1093\/infdis\/jiy176","volume":"218","author":"Wijting I.E.A.","year":"2018","unstructured":"Wijting I.E.A.; Lungu C.; Rijnders B.J.A.; van der Ende M.E.; Pham H.T.; Mesplede T.; Pas S.D.; Voermans J.J.C.; Schuurman R.; van de Vijver D.A.M.C.; Boers P.H.M.; Gruters R.A.; Boucher C.A.B.; van Kampen J.J.A.; HIV-1 resistance dynamics in patients with virologic failure to dolutegravir maintenance monotherapy. J Infect Dis 2018,218(5),688-697","journal-title":"J Infect Dis"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.2174\/0929867324666170113110839","volume":"25","author":"Wang X.","year":"2018","unstructured":"Wang X.; Gao P.; Menendez-Arias L.; Liu X.; Zhan P.; Update on recent developments in small molecular HIV-1 RNase H inhibitors (2013-2016): Opportunities and challenges. Curr Med Chem 2018,25(14),1682-1702","journal-title":"Curr Med Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.4155\/fmc.13.178","volume":"5","author":"Corona A.","year":"2013","unstructured":"Corona A.; Masaoka T.; Tocco G.; Tramontano E.; Le Grice S.F.; Active site and allosteric inhibitors of the ribonuclease H activity of HIV reverse transcriptase. Future Med Chem 2013,5(18),2127-2139","journal-title":"Future Med Chem"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.2174\/092986710792065045","volume":"17","author":"Tramontano E.","year":"2010","unstructured":"Tramontano E.; Di Santo R.; HIV-1 RT-associated RNase H function inhibitors: Recent advances in drug development. Curr Med Chem 2010,17(26),2837-2853","journal-title":"Curr Med Chem"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3390\/biology1030521","volume":"1","author":"Ilina T.","year":"2012","unstructured":"Ilina T.; Labarge K.; Sarafianos S.G.; Ishima R.; Parniak M.A.; Inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H activity. Biology (Basel) 2012,1(3),521-541","journal-title":"Biology (Basel)"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1517\/14728222.6.4.433","volume":"6","author":"Andr\u00e9ola M.L.D.S.","year":"2002","unstructured":"Andr\u00e9ola M.L.D.S.; De Soultrait V.R.; Fournier M.; Parissi V.; Desjobert C.; Litvak S.; HIV-1 integrase and RNase H activities as therapeutic targets. Expert Opin Ther Targets 2002,6(4),433-446","journal-title":"Expert Opin Ther Targets"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"23873","DOI":"10.1039\/C8CP01843J","volume":"20","author":"Yang F.","year":"2018","unstructured":"Yang F.; Zheng G.; Fu T.; Li X.; Tu G.; Li Y.H.; Yao X.; Xue W.; Zhu F.; Prediction of the binding mode and resistance profile for a dual-target pyrrolyl diketo acid scaffold against HIV-1 integrase and reverse-transcriptase-associated ribonuclease H. Phys Chem Chem Phys 2018,20(37),23873-23884","journal-title":"Phys Chem Chem Phys"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ejmech.2019.06.058","volume":"179","author":"Gill M.S.A.","year":"2019","unstructured":"Gill M.S.A.; Hassan S.S.; Ahemad N.; Evolution of HIV-1 reverse transcriptase and integrase dual inhibitors: Recent advances and developments. Eur J Med Chem 2019,179,423-448","journal-title":"Eur J Med Chem"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.drudis.2015.07.012","volume":"20","author":"Su M.","year":"2015","unstructured":"Su M.; Tan J.; Lin C.Y.; Development of HIV-1 integrase inhibitors: Recent molecular modeling perspectives. Drug Discov Today 2015,20(11),1337-1348","journal-title":"Drug Discov Today"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.4155\/fmc.10.193","volume":"2","author":"Liao C.","year":"2010","unstructured":"Liao C.; Nicklaus M.C.; Computer tools in the discovery of HIV-1 integrase inhibitors. Future Med Chem 2010,2(7),1123-1140","journal-title":"Future Med Chem"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"4644","DOI":"10.1080\/07391102.2018.1557559","volume":"37","author":"Samorlu A.S.Y.","year":"2019","unstructured":"Samorlu A.S.Y.; Yelek\u00e7i K.; Ibrahim Uba A.; The design of potent HIV-1 integrase inhibitors by a combined approach of structure-based virtual screening and molecular dynamics simulation. J Biomol Struct Dyn 2019,37(17),4644-4650","journal-title":"J Biomol Struct Dyn"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/07391102.2017.1420489","volume":"37","author":"Vora J.","year":"2019","unstructured":"Vora J.; Patel S.; Sinha S.; Sharma S.; Srivastava A.; Chhabria M.; Shrivastava N.; Molecular docking, qsar and admet based mining of natural compounds against prime targets of HIV. J Biomol Struct Dyn 2019,37(1),131-146","journal-title":"J Biomol Struct Dyn"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3389\/fchem.2019.00574","volume":"7","author":"Sirous H.","year":"2019","unstructured":"Sirous H.; Chemi G.; Gemma S.; Butini S.; Debyser Z.; Christ F.; Saghaie L.; Brogi S.; Fassihi A.; Campiani G.; Brindisi M.; Identification of novel 3-Hydroxy-pyran-4-one derivatives as potent HIV-1 integrase inhibitors using in silico structure-based combinatorial library design approach. Front Chem 2019,7,574","journal-title":"Front Chem"},{"key":"ref=29","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2019.e02811","volume":"5","author":"Eurtivong C.","year":"2019","unstructured":"Eurtivong C.; Choowongkomon K.; Ploypradith P.; Ruchirawat S.; Molecular docking study of lamellarin analogues and identification of potential inhibitors of HIV-1 integrase strand transfer complex by virtual screening. Heliyon 2019,5(11)","journal-title":"Heliyon"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ejmech.2016.04.019","volume":"117","author":"Patel S.B.P.","year":"2016","unstructured":"Patel S.B.P.; Patel B.D.; Pannecouque C.; Bhatt H.G.; Design, synthesis and anti-HIV activity of novel quinoxaline derivatives. Eur J Med Chem 2016,117,230-240","journal-title":"Eur J Med Chem"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2174\/1568026615666150813150433","volume":"16","author":"Guasch L.","year":"2016","unstructured":"Guasch L.; Zakharov A.V.; Tarasova O.A.; Poroikov V.V.; Liao C.; Nicklaus M.C.; Novel HIV-1 integrase inhibitor development by virtual screening based on qsar models. Curr Top Med Chem 2016,16(4),441-448","journal-title":"Curr Top Med Chem"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1039\/C5MB00767D","volume":"12","author":"Islam M.A.P.","year":"2016","unstructured":"Islam M.A.P.; Pillay T.S.; Structural requirements for potential HIV-integrase inhibitors identified using pharmacophore-based virtual screening and molecular dynamics studies. Mol Biosyst 2016,12(3),982-993","journal-title":"Mol Biosyst"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1039\/C7MD00600D","volume":"9","author":"Poongavanam V.","year":"2018","unstructured":"Poongavanam V.; Corona A.; Steinmann C.; Scipione L.; Grandi N.; Pandolfi F.; Di Santo R.; Costi R.; Esposito F.; Tramontano E.; Kongsted J.; Structure-guided approach identifies a novel class of HIV-1 ribonuclease H inhibitors: Binding mode insights through magnesium complexation and site-directed mutagenesis studies. MedChemComm 2018,9(3),562-575","journal-title":"MedChemComm"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/jcc.22887","volume":"33","author":"Xue W.","year":"2012","unstructured":"Xue W.; Liu H.; Yao X.; Molecular mechanism of HIV-1 integrase-vDNA interactions and strand transfer inhibitor action: A molecular modeling perspective. J Comput Chem 2012,33(5),527-536","journal-title":"J Comput Chem"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1021\/ci300541c","volume":"53","author":"Xue W.","year":"2013","unstructured":"Xue W.; Jin X.; Ning L.; Wang M.; Liu H.; Yao X.; Exploring the molecular mechanism of cross-resistance to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis. J Chem Inf Model 2013,53(1),210-222","journal-title":"J Chem Inf Model"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"734","DOI":"10.2174\/1386207320666170615104703","volume":"20","author":"Chander S.","year":"2017","unstructured":"Chander S.; Pandey R.K.; Penta A.; Choudhary B.S.; Sharma M.; Malik R.; Prajapati V.K.; Murugesan S.; Molecular docking and molecular dynamics simulation based approach to explore the dual inhibitor against HIV-1 reverse transcriptase and integrase. Comb Chem High Throughput Screen 2017,20(8),734-746","journal-title":"Comb Chem High Throughput Screen"},{"key":"ref=37","first-page":"36","volume":"7","author":"Chen Q.","year":"2015","unstructured":"Chen Q.; Cheng X.; Wei D.; Xu Q.; Molecular dynamics simulation studies of the wild type and E92Q\/N155H mutant of Elvitegravir-resistance HIV-1 integrase. Interdiscip Sci 2015,7(1),36-42","journal-title":"Interdiscip Sci"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nature08784","volume":"464","author":"Hare S.","year":"2010","unstructured":"Hare S.; Gupta S.S.; Valkov E.; Engelman A.; Cherepanov P.; Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010,464(7286),232-236","journal-title":"Nature"},{"key":"ref=39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0223464","volume":"15","author":"Chitongo R.","year":"2020","unstructured":"Chitongo R.; Obasa A.E.; Mikasi S.G.; Jacobs G.B.; Cloete R.; Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-dolutegravir binding. PLoS One 2020,15(5)","journal-title":"PLoS One"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1093\/jac\/dkx529","volume":"73","author":"Malet I.","year":"2018","unstructured":"Malet I.; Ambrosio F.A.; Subra F.; Herrmann B.; Leh H.; Bouger M.C.; Artese A.; Katlama C.; Talarico C.; Romeo I.; Alcaro S.; Costa G.; Deprez E.; Calvez V.; Marcelin A.G.; Delelis O.; Pathway involving the N155H mutation in HIV-1 integrase leads to dolutegravir resistance. J Antimicrob Chemother 2018,73(5),1158-1166","journal-title":"J Antimicrob Chemother"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2174\/1570162X14666160321120232","volume":"14","author":"Riemenschneider M.","year":"2016","unstructured":"Riemenschneider M.; Heider D.; Current approaches in computational drug resistance prediction in HIV. Curr HIV Res 2016,14(4),307-315","journal-title":"Curr HIV Res"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1097\/00002030-200008180-00007","volume":"14","author":"Schmidt B.","year":"2000","unstructured":"Schmidt B.; Walter H.; Moschik B.; Paatz C.; van Vaerenbergh K.; Vandamme A.M.; Schmitt M.; Harrer T.; Uberla K.; Korn K.; Simple algorithm derived from a geno-\/phenotypic database to predict HIV-1 protease inhibitor resistance. AIDS 2000,14(12),1731-1738","journal-title":"AIDS"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2174\/1574893610666151008011731","author":"Bonet I.","year":"2015","unstructured":"Bonet I.; Machine Learning for Prediction of HIV Drug Resistance: A Review. Curr Bioinform 2015(10),579-585","journal-title":"Curr Bioinform"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2174\/1570162X13666150624100535","volume":"13","author":"Masso M.","year":"2015","unstructured":"Masso M.; Sequence-based predictive models of resistance to HIV-1 integrase inhibitors: An n-grams approach to phenotype assessment. Curr HIV Res 2015,13(6),497-502","journal-title":"Curr HIV Res"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/s12859-019-2991-2","volume":"20","author":"Ramon E.","year":"2019","unstructured":"Ramon E.; Belanche-Mu\u00f1oz L.; P\u00e9rez-Enciso M.; HIV drug resistance prediction with weighted categorical kernel functions. BMC Bioinformatics 2019,20(1),410","journal-title":"BMC Bioinformatics"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"221","DOI":"10.6026\/97320630012221","volume":"12","author":"Sachithanandham J.","year":"2016","unstructured":"Sachithanandham J.; Konda Reddy K.; Solomon K.; David S.; Kumar Singh S.; Vadhini Ramalingam V.; Alexander Pulimood S.; Cherian Abraham O.; Rupali P.; Sridharan G.; Kannangai R.; Effect of HIV-1 Subtype C integrase mutations implied using molecular modeling and docking data. Bioinformation 2016,12(3),221-230","journal-title":"Bioinformation"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.meegid.2018.11.014","volume":"68","author":"da Silva H.H.S.A.","year":"2019","unstructured":"da Silva H.H.S.A.; Pereira N.; Brand\u00e3o L.; Crovella S.; Moura R.; Prediction of HIV integrase resistance mutation using in silico approaches. Infect Genet Evol 2019,68,10-15","journal-title":"Infect Genet Evol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1126\/science.aay8015","volume":"367","author":"Passos D.O.L.","year":"2020","unstructured":"Passos D.O.L.; Li M.; J\u00f3\u017awik I.K.; Zhao X.Z.; Santos-Martins D.; Yang R.; Smith S.J.; Jeon Y.; Forli S.; Hughes S.H.; Burke T.R.; Craigie R.; Lyumkis D.; Structural basis for strand-transfer inhibitor binding to HIV intasomes. Science 2020,367(6479),810-814","journal-title":"Science"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jmgm.2013.08.012","volume":"46","author":"Sohn Y.S.P.","year":"2013","unstructured":"Sohn Y.S.P.; Park C.; Lee Y.; Kim S.; Thangapandian S.; Kim Y.; Kim H.H.; Suh J.K.; Lee K.W.; Multi-conformation dynamic pharmacophore modeling of the peroxisome proliferator-activated receptor \u03b3 for the discovery of novel agonists. J Mol Graph Model 2013,46,1-9","journal-title":"J Mol Graph Model"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nrd2082","volume":"5","author":"Copeland R.A.P.","year":"2006","unstructured":"Copeland R.A.P.; Pompliano D.L.; Meek T.D.; Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 2006,5(9),730-739","journal-title":"Nat Rev Drug Discov"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"4552","DOI":"10.1128\/AAC.00157-11","volume":"55","author":"Hightower K.E.W.","year":"2011","unstructured":"Hightower K.E.W.; Wang R.; Deanda F.; Johns B.A.; Weaver K.; Shen Y.; Tomberlin G.H.; Carter H.L.; Broderick T.; Sigethy S.; Seki T.; Kobayashi M.; Underwood M.R.; Dolutegravir (S\/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother 2011,55(10),4552-4559","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1021\/bi802141y","volume":"48","author":"Garvey E.P.S.","year":"2009","unstructured":"Garvey E.P.S.; Schwartz B.; Gartland M.J.; Lang S.; Halsey W.; Sathe G.; Carter H.L.; Weaver K.L.; Potent inhibitors of HIV-1 integrase display a two-step, slow-binding inhibition mechanism which is absent in a drug-resistant T66I\/M154I mutant. Biochemistry 2009,48(7),1644-1653","journal-title":"Biochemistry"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867328666210708090123","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/194594\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867328666210708090123","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T13:44:01Z","timestamp":1665495841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/194594\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867328666210708090123","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-02-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}